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Abstract
Background: The generation of new immunogens able to elicit strong specific immune responses remains a major
challenge in the attempts to obtain a prophylactic or therapeutic vaccine against HIV/AIDS. We designed and constructed
a defective recombinant virus based on the HIV-1 genome generating infective but non-replicative virions able to elicit
broad and strong cellular immune responses in HIV-1 seropositive individuals.
Results: Viral particles were generated through transient transfection in producer cells (293-T) of a full length HIV-1 DNA
carrying a deletion of 892 base pairs (bp) in the pol gene encompassing the sequence that codes for the reverse
transcriptase (NL4-3/DRT clone). The viral particles generated were able to enter target cells, but due to the absence of
reverse transcriptase no replication was detected. The immunogenic capacity of these particles was assessed by ELISPOT to
determine c-interferon production in a cohort of 69 chronic asymptomatic HIV-1 seropositive individuals. Surprisingly,
defective particles produced from NL4-3/DRT triggered stronger cellular responses than wild-type HIV-1 viruses inactivated
with Aldrithiol-2 (AT-2) and in a larger proportion of individuals (55% versus 23% seropositive individuals tested). Electron
microscopy showed that NL4-3/DRT virions display immature morphology. Interestingly, wild-type viruses treated with
Amprenavir (APV) to induce defective core maturation also induced stronger responses than the same viral particles
generated in the absence of protease inhibitors.
Conclusions: We propose that immature HIV-1 virions generated from NL4-3/DRT viral clones may represent new
prototypes of immunogens with a safer profile and stronger capacity to induce cellular immune responses than wild-type
inactivated viral particles.
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Introduction
The generation of new immunogens able to elicit strong specific
immune responses remains a major challenge in the attempts to
obtain a prophylactic or therapeutic vaccine against HIV/AIDS
[1,2]. Whereas in the context of prophylactic vaccines the role of
cellular responses in protecting against infection is unknown, in
HIV-infected individuals the improvement of cellular HIV-specific
immune responses appears to contribute to viral load control, both
in animal models and clinical trials [3–7]. Strategies previously
used to trigger strong cellular responses include immunization with
defective viruses, inactivated viral particles, viral vectors expressing
HIV-1 proteins and DNA [8,9]. Inactivated viral particles display
low immunogenicity due to modifications in protein structure and
their lack of replicating capacity [10]. In contrast, live-attenuated
virus vaccines have proved very successful in inducing strong
cellular and humoral responses against SIV in macaque models
[11–13]. However, for reasons of safety immunization with live-
attenuated viruses is not recommended in the context of pro-
phylactic vaccines due to the persistence of the attenuated virus in
combination with ongoing low-level replication [14,15]. In this
setting, the error-prone replication machinery of the virus may
eventually lead to the generation of wild-type pathogenic virus
variants [16–18]. Alternatively, a virus that can execute only
a single round of replication or conditionally live HIV-1 virus in
which replication can be turned on and off at will can be used as
a vaccine [19–22]. However, due to their limited replication,
single-cycle virus vaccines of this kind may be less potent for the
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induction of protective immunity [15]. To improve safety, vaccine
strains can be further attenuated through additional deletions or
mutations in accessory genes or regulatory elements in order to
reduce the pathogenicity of the virus [23]. Another approach
could be to delete genes coding for critical enzymes involved in the
viral cycle such as integrase or reverse transcriptase (RT).
Recently, a DNA vaccine carrying a RT deletion has been
assayed in macaques and although no protection was obtained, the
induction of cellular immune responses led to decreased viral
replication in vaccinated animals [24,25]. The currently favoured
subunit vaccines contain only a single or a few selected antigens
due to the cost and manufacturing restrictions of producing
a broad protein repertoire in their native structure. Virus-like
particles (VLP) have recently emerged as an alternative to subunit
vaccines, offering the advantage of mimicking the natural
conformation of the capsid or envelope; they self-assemble into
particulate structures, closely resembling the natural virus from
which they are derived. VLPs are incapable of replication or
infection, lacking regulatory proteins as well as infective genetic
material [26].
Another approach to the development of therapeutic vaccines
involves dendritic cell-based therapy, which is able to induce both
primary and secondary immune responses of CD4+ and CD8+ T
lymphocytes [27–29]. These cells present antigens not only in the
MHC-class II pathway to helper CD4+ T cells but also in the
MHC-class I pathway to cytotoxic CD8+ T lymphocytes [30,31].
Several clinical trials based on dendritic cell immunotherapy for
HIV infection have been reported [32]. Most of them found that
DC immunotherapy elicits immunological responses, even though
the design of the trials and the HIV antigens used to pulse
dendritic cells were very different. Few of these trials have been
performed with monocyte-derived dendritic cells from HIV-
infected individuals which are cultured in vitro and pulsed with
autologous viruses inactivated by different methods [33,34].
Recently, in an uncontrolled study Routy et al. [35] reported the
final results of an immunotherapy consisting of MD-DCs
electroporated with mRNA encoding autologous HIV-1 antigens
(Gag, Nef, Rev, Vpr). However, these studies have shown the
induction of cellular responses and partial viral load control in
some individuals [33–35].
The midterm success of these dendritic-cell therapeutic vaccines
has been limited and, more importantly, they face major technical
limitations. First, the generation of autologous viruses in Good
Manufacturing Practices (GMP) conditions is expensive, time
consuming and impractical when a large number of individuals is
considered. Second, inactivation procedures such as heating result
in protein degradation and decreased immunogenicity. Finally,
inactivation methods decrease viral infectivity up to four logs, but
residual viral activity remains [33,34,36]. To overcome these
obstacles we have generated a defective recombinant virus based
on the HIV-1 genome in which the RT is partially deleted (NL4-
3/DRT). This vector generates infective but non-replicative
particles when transfected in a producer cell line (293-T). We
show that stimulating peripheral blood mononuclear cells
(PBMCs) from HIV-infected individuals with NL4-3/DRT viral
particles induces stronger cellular immune responses against HIV-
1 than inactivated viral particles generated from a wild-type HIV-
1 vector. The increased immunogenicity is probably related to the
immature morphology of NL4-3/DRT virions. We propose that
these non-replicative vectors could be used as safer immunogens
for therapeutic immunization with dendritic cell-based HIV
vaccines.
Results
Proviral NL4-3/DRT Clone Generates Infectious Non-
replicative Viruses
Defective particles were produced by transient transfection of
293-T cells with a full length HIV-1 DNA carrying a deletion of
892 bp in the pol gene, encompassing the reverse transcriptase
sequence (Figure 1). Viral production was examined at 48 or 72
hours post-transfection by an in vitro p24 ELISA assay and no
significant difference was observed between pNL4-3 and pNL4-3/
DRT transient transfection (data not shown). To evaluate the
ability of NL4-3/DRT virions to promote the early steps of the
retroviral replicative cycle, we produced virions carrying the Gag-
EGFP fusion protein to monitor them. Confocal microscopy
analysis of 293-T transiently transfected cells showed a cytoplasmic
and membrane expression of Gag-EGFP (data not shown). Virions
produced in cells expressing Gag-EGFP incorporated this fusion
protein during their budding. PBMCs activated with IL-2 and
PHA for two days were incubated with supernatant from 293-T
transfected cells carrying virions labelled with Gag-EGFP. Three
hours after incubation, PBMC were fixed, stained and analysed by
confocal microscopy. In contrast to PBMCs incubated with pGag-
EGFP supernatant, those incubated with NL4-3 plus Gag-EGFP
or an NL4-3/DRT plus Gag-EGFP displayed EGFP punctuated
areas (Figure 2A), showing that both NL4-3 and NL4-3/DRT
virions were able to enter the cells.
The ability of the NL4-3/DRT to replicate was evaluated in
TZM-bl cells, which carry a luciferase reporter under the control
of the HIV-1 LTR promoter. Virus stocks prepared by transient
transfection and normalized by the amount of p24 capsid protein
were used to infect TZM-bl cells. Replication was determined by
counting the luciferase activity of the cells three days post-
infection. In contrast to NL4-3 virions, which show a replication
correlative to the amount of p24 (Figure 2B), NL4-3/DRT
virions were found to be non-replicative regardless of the amount
of p24.
These results showed that NL4-3/DRT virions were able to
enter cells but unable to produce new progeny due to the absence
of retrotranscriptase activity.
NL4-3/DRT Virion Morphology
Most HIV-1 virions appear as 110 nm diameter spherical
particles with an electron-dense ring at the periphery surrounding
a translucent core (immature morphology particles). Briefly, after
the release of the virion, free capsid protein, cleaved from Gag
polyprotein by the viral protease, is associated into a conical core
structure at the centre of the particle, and the electron-dense ring
at the periphery disappears (mature morphology particles). To
check if the absence of the retrotranscriptase protein alters virion
morphology or structure, electron microscopy analysis of 293-T
cells transfected with pNL4-3 and pNL4-3/DRT was performed.
Two days post-transfection with pNL4-3, electron micrographs
showed the characteristic mature viral particles as well as budding
virions (Figure 3A). However, the morphology of NL4-3/DRT
virions close to the plasma membrane or during their budding was
spherical, with two electron-dense layers surrounding a translucent
centre, clearly resembling immature particles (Figure 3B). To
confirm the immature morphology of NL4-3/DRT virions, we
analysed ultracentrifugated purified virions by electron microsco-
py. Four hundred and sixty NL4-3 particles from 10 different
micrographs were quantified and 85% showed the typical mature
morphology with the canonical core structure in the middle
(Figure 3E), the remaining 15% being immature and eccentric
virions (Figures 3C and 3G). In contrast, 97% of the 585 NL4-
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3/DRT purified particles quantified in 10 different micrographs
were immature viruses with a spherical shape surrounded by a ring
of two electron-dense layers (Figure 3F). The rest of the particles
could be classified as eccentric and non-determined forms, no
mature particles were observed (Figures 3D and 3G).
The immature morphology of NL4-3/DRT virions suggested
a problem in the Gag polyprotein processing by the viral protease.
Western blot analysis of equal quantities of NL4-3 and NL4-3/
DRT purified virions was performed to evaluate the viral
processing. Using an anti-p24 monoclonal antibody, we confirmed
that the processing of Gag polyprotein in NL4-3 purified virions
was complete as shown by the presence of p24 and the loss of
nearly complete p55-gag and MA-CA-p41 (Figure 4). NL4-3/
DRT purified virions processed Gag polyprotein into CA p24;
however, intermediate forms such as p55-gag and MA-CA-p41
were still present, suggesting an incomplete processing that could
explain the immature morphology of the virions.
NL4-3/DRT Virions were able to Induce Specific-cellular
Immune-responses
We assessed the immunogenic capacity of NL4-3/DRT virions
by a classical ELISPOT assay evaluating the presence of T-specific
IFN-c producing cells by testing a panel of PBMC samples from
chronic asymptomatic HIV-infected individuals (n = 69). In
parallel, we also used Aldrithiol-2 (AT-2) inactivated NL4-3 and
NL4-3/DRT virions, which did not produce replicative viruses.
To rule out false-positive T-cell responses and to confirm the
specificity of our approach we also performed ELISPOT assays
using samples from healthy HIV-uninfected individuals and
preparations of viral particles obtained from supernatants of
293-T cells transfected with irrelevant plasmids. As expected, no
positive response was detected in either case. Surprisingly, NL4-3/
DRT defective particles triggered cellular responses in a larger
proportion of individuals (55% of individuals) than AT-2
inactivated wild type NL4-3 viruses, in which case only 23% of
individuals responded. It should be noted that the latter 23%
responded to both AT-2 inactivated NL4-3 and NL4-3/DRT
whereas an additional 32% of individuals only responded to NL4-
3/DRT and not to AT-2 inactivated NL4-3 viruses. Moreover,
AT-2 treatment did not affect the induction of cellular immune
responses, since the number of individuals who showed positive
responses (63%) was even higher. Evaluating the magnitude of the
elicited immune response, we observed that the mean of the SFC/
106 PBMC obtained after exposure to NL4-3/DRT viruses was
significantly higher than after using NL4-3 treated with AT-2 (454
vs 259 SFC/106 PBMC respectively; p,0.005), even increasing
the concentrations of both viruses (figures 5A and 5B). We also
observed that the mean of the immune response elicited with AT-2
treated NL4-3/DRT virions was significantly higher (712 SFC/
106 PBMC) than with AT-2 inactivated NL4-3 viruses, and also
higher than with NL4-3/DRT virions. This latter result may
suggest that AT-2 treatment did not impair the immunogenicity of
defective viruses and probably indicates that this chemical
inactivation was not deleterious for the integrity of this viral
construct.
Effect of Amprenavir (APV) Virus Treatment on the
Immunogenic Capacity
To assess whether the immaturity status of the defective viruses
might be involved in their immunogenic capacity, we decided to
generate immature NL4-3 viruses through treatment with the
protease inhibitor APV, which has previously been shown to block
virus infectivity and render particles immature [37]. Electron
microscopy analyses showed that most of the particles had an
eccentric immature morphology with an electron-dense patch on
one side (Figure 6A). Six hundred and eighteen particles from 52
different micrographs showed that 67% of the particles appeared
to be eccentric and 12% immature, compared with 7% that were
mature (Figure 6B).
ELISPOT analysis (n = 21) was applied to AT-2 inactivated
NL4-3 viruses generated either in the presence or absence of APV.
The ability to generate an immune response was increased when
using immature AT-2 inactivated NL4-3 viruses treated with APV
(obtaining immune response in 67% versus 33%), being similar to
the proportion of HIV-infected patients able to respond to NL4-3/
DRT. In addition, analysing the response magnitude, we observed
that the SFC/106 PBMC mean was significantly lower (p,0.05) in
the case of AT-2 inactivated NL4-3 viruses in comparison with
AT-2 inactivated NL4-3 treated with APV (455 vs.1092 SFC/106
PBMC) respectively (Figure 6C).
Discussion
Current antiretroviral treatment can control viral load and
immune recovery but combined Active Antiretroviral Therapy
(cART) does not eradicate the virus [38]. Consequently, treatment
must be maintained for the entire lifetime, with the risk of
secondary effects and emergence of resistances, and at a high
economic cost. Therapeutic vaccination, aiming at the induction
of cellular immune responses able to control HIV replication, is an
Figure 1. NL4-3/DRT plasmid graphic scheme. NL4-3 (WT) plasmid was used to generate the NL4-3/DRT plasmid by deleting an 892 bp
fragment, which codes for the retrotranscriptase (RT) and is inside the pol gene. These plasmids were used to transfect 293-T cells in order to obtain
viruses. Numbers refer to pNL4-3.
doi:10.1371/journal.pone.0048848.g001
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alternative to chronic cART [1]. Inactivated viruses, poxvirus
vectors, virus-like particles and dendritic cell-based vaccines have
all been assayed in clinical trials, albeit with limited success
[9,33,36,39].
Figure 2. NL4-3/DRT plasmid renders virions infectious but non-replicative. (A) PBMC infection was monitored using NL4-3 (WT) and NL4-3/
DRT (DRT) virions labelled with a Gag fusion protein (Gag-EGFP). Samples were imaged using a Leica SP2 confocal microscope. We observed an
accumulation of Gag-EGFP in the cells infected with NL4-3 and NL4-3/DRT (arrows) but not in cells infected with Gag-EGFP. Cellular nuclei are stained
in blue (DAPI), F-actin in red (Phalloidine) and the fusion protein Gag in green (Gag-EGFP). (B) NL4-3 and NL4-3/DRT virion replication measurements
by luciferase activity in TZM-bl cells. The NL4-3 virions showed a decrease in luciferase activity directly proportional to the p24 quantity, while for NL4-
3/DRT virions, luciferase activity was under the background independently of the p24 quantity.
doi:10.1371/journal.pone.0048848.g002
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Since reverse transcription of retroviral genomes into double
stranded DNA is a key event for viral replication, we constructed
and characterized a defective recombinant vector based on the
HIV-1 genome in which only 892 bp of the RT gene were deleted,
including RT fingers, palms and thumb subdomains (pNL4-3/
DRT; Figure 1), to serve as immunogen candidate in therapeutic
HIV vaccines. We demonstrate that RT deleted viral particles are
able to infect target cells (Figure 2A) but do not allow a new cycle
of replication in the infected cell (Figure 2B). The safety of viral
constructs generating full viral genomes is a matter of major
concern, particularly in the context of already infected individuals
in whom recombination events may potentially occur. In the case
of co-infection of the same cell by NL4-3/DRT particles and wild
type-virus, trans-activity of reverse transcriptase from the latter
could result in retrotranscription of the defective NL4-3/DRT
RNA and generation of recombinant HIV-DNA susceptible to
integration and subsequent replication. To avoid this possibility we
performed the 892 bp deletion mentioned above that encompasses
Figure 3. Analysis of virion morphologies by electron microscopy. (A) Electron micrographic analysis of 293-T cells transfected with pNL4-3.
Mature virions (black arrows) show their characteristic core (white arrow heads). Budding particles (black arrow heads) are also present. (B) Electron
micrograph showing immature viral particles budding from 293-T cells transfected with pNL4-3/DRT (black arrows). (C) Electron micrographic analysis
of pNL4-3 purified viruses showing mature, immature and eccentric virion forms. (D) Electron micrograph of pNL4-3/DRT purified virions in which
only immature virion forms can be observed. (E and F) NL4-3 and NL4-3/DRT virion magnifications respectively are shown. (G) Virion form
measurements of NL4-3 versus NL4-3/DRT. NL4-3/DRT virion conformation was mostly immature and no mature virions were observed. On the other
hand, NL4-3 virions were mainly mature. Error bars represent standard deviations. Samples were imaged using a Tecnai Spirit Twin electron-
microscope.
doi:10.1371/journal.pone.0048848.g003
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the thumb subdomain in the RT, which is required for the
tRNALys3 packaging into HIV-1 [40]. The absence of the RT
sequence avoids the formation of the tRNA/LysRS and blocks the
annealing to the viral RNA [41]. This deletion therefore blocks the
formation of the reverse transcription initiation complex, even
when RT molecules from co-infecting wild type virus cells are
present [42,43]. As a complementary strategy to prevent re-
combination events, the administration of antiviral drugs at the
same time as vaccination could be envisaged [44].
The use of other viral constructs like Integrase-defective
lentiviruses has been proposed as a strategy for the safe
immunization. In vitro and in vivo data [45,46] show that these
vectors display appropriate immunogenicity that is comparable to
vaccination with wild type vectors. However, even though
integration is blocked, reverse transcription and generation of
HIV-DNA molecules are produced. It has recently been reported
that exposure to cytoplasmic DNA products elicits antiviral
responses leading to activation of caspases and massive apoptosis
through a bystander phenomenon in non-infected lymphocytes
[47].
Conversely, inhibition of early reverse transcription results in
decreased toxicity through this pro-apoptotic mechanism. There-
fore, compared to integrase-deleted viruses, our NL4-3DRT
vectors, which do not allow retrotranscription and DNA synthesis,
would improve the safety of the immunogen. We show that viral
particles generated from NL4-3/DRT vectors are able to induce
a significant immune response when used in vitro in PBMC cultures
from infected individuals. Interestingly, when PBMCs from 69
chronic asymptomatic HIV-infected individuals were stimulated
with NL4-3 and NL4-3/DRT viral particles, a higher number of
subjects responded to NL4-3/DRT particles than to AT-2
inactivated NL4-3 virions (55% versus 23% individuals). Moreover
the number of IFN-c producing cells was increased in PBMCs
stimulated with NL4-3/DRT virions. Therefore, NL4-3/DRT
particles increased both the proportion of responders to HIV
antigens and the magnitude of cellular responses. One possible to
explanation for this finding is that AT-2 treatment may decrease
the immunogenicity of viral particles [48]. However, when we
tested this hypothesis through AT-2 inactivation of NL4-3/DRT
Figure 4. Protein profile of NL4-3 and NL4-3/DRT virions. Virions
purified by ultracentrifugation were used to extract proteins and
separated in a gradient 4-12% Tris-Glycine gel. An anti-p24 monoclonal
antibody was used to study the processing profile of Gag in NL4-3/DRT
and NL4-3 virions. There is a weaker processing of Gag in NL4-3/DRT
virions, represented by an increase in p55-gag and MA-CA p41 forms in
detriment of CA p24. At the same, an increase in intermediate forms is
also shown in NL4-3/DRT virions.
doi:10.1371/journal.pone.0048848.g004
Figure 5. Immunogenicity of different viral constructions measured by ELISPOT responses. (A) Cryopreserved PBMCs from asymptomatic
HIV seropositive individuals were tested for specific IFN-c secreting T cells by in vitro stimulation with different HIV virions (WT+AT-2, DRT and
DRT+AT-2). PBMCs were pulsed with 200 ng/ml p24 equivalents in all cases. The response elicited by WT+AT-2, DRT and DRT+AT-2 virions (mean 6
SEM) is shown. The positivity threshold for each construct or antigen was defined as at least 50 SFC/106 PBMC and at least twice that of the control
medium. The magnitude of response differed significantly between stimuli (***p,0.001). (B) Four responder individuals were tested with different
concentrations of WT+AT-2 and DRT virions (from 200 ng/ml to 5 mg/ml). The titration showed that the difference found between both stimuli was
maintained, independently of the amount of virions used.
doi:10.1371/journal.pone.0048848.g005
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particles, even a higher immunogenic activity was found, a result
that rules out this mechanism. Another difference between NL4-3
and NL4-3/DRT virions that could explain the differences in
immunogenicity was the immature morphology in the capsid. In
fact, in electron microscopy analysis we observed that more than
97% of NL4-3/DRT viral particles displayed an immature
morphology (Figures 3B, D and F). Differences in viral
maturation was confirmed by Western blot of virions produced
by wild type or NL4-3/DRT vectors, as shown by a sharp decrease
in p55-gag processing and lower generation of mature CA p24
protein (figure 4). So far, the generation of immature particles has
been documented after treatment with protease inhibitors,
mutations of protease cleavage sites in Gag or by inhibitors of
Gag processing [49-51]. However, it has been reported that
mutations in the RT gene affect virion maturation and RNA
dimer stability [52]. Besides, cleavage of p55-gag is required for
RNA dimerization and further virion maturation [53]. Overall,
these results suggest that viral RT sequences play a role in the
control of protease activity and viral maturation, as we found in
our experiments (figure 4). This mechanism could explain the
generation of immature particles by our NL4-3/DRT constructs,
which in turn, would further improve safety.
Interestingly, viral preparations produced by NL4-3/DRT
vectors induced higher proportions of IFN-c producing cells,
raising the possibility that immature particles may be more
immunogenic than wild-type virions. To test this hypothesis we
generated virions from a wild-type HIV-1 genome in the presence
of a protease inhibitor (APV) [37]. Immature virions with eccentric
core morphology were observed by electron microscopy
(Figure 6A) and these AT-2 inactivated viral preparations
displayed stronger immunogenicity than AT-2 treated wild type
viruses (NL4-3) generated in the absence of a protease inhibitor
(Figure 6C). We therefore conclude that immature viral particles
display higher potency as viral immunogens [54,55] and that this is
probably the underlying mechanism responsible for the stronger
induction of cellular responses observed with NL4-3/DRT viruses.
A possible explanation for this observation is that immature
particles are more stable, increasing the exposure of important
epitopes on their surface [56], leading to higher loads of viral
proteins in presenting cells and increased abundance of peptides
generated by proteolytic processing. Actually, previous reports
have shown that dendritic cells can cross-present virus-like
particles using an endosome-to-cytosol pathway [57,58]. NL4-3/
DRT immature particles may be preferentially directed towards
this pathway of protein processing and antigen cross-presentation
by specialized presenting cells that induce efficient immune
responses in PBMC cultures [59,60]. Overall, these data suggest
that immature, defective non-replicative viruses may be good
candidates as imunogens due to their greater capacity to induce
specific immune responses.
Figure 6. Immature NL4-3 virions improved the elicited cellular
immune response. (A) Electron microscopy analysis of purified NL4-3
virions treated with AT-2 and APV. Different virion morphologies were
observed; most were immature and eccentric. (B) 52 electron-
micrographs were analysed for virus morphologies. The APV incubation
reduces mature virions but increases immature and eccentric forms.
Error bars represent standard deviaations. (C) Twenty-one cryopre-
served PBMCs from HIV seropositive individuals were assessed by
ELISPOT to detect IFN-c production. PBMCs were pulsed with 200 ng/
ml p24 equivalents in all cases. Magnitude response was significantly
lower against WT inactivated virions (WT+AT-2) than against WT+AP-
V+AT-2 (*p,0.05). Averaged values from duplicate wells normalized to
SFC/106 PBMCs are shown for the stimulation conditions indicated.
Plots represent mean 6 standard error of the mean (SEM). Positivity
threshold for each construct or antigen was defined as at least 50 SFC/
106 PBMC and at least twice that of the control medium.
doi:10.1371/journal.pone.0048848.g006
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Since HIV is a highly variable retrovirus, and since differences
in sequence between two viruses within a subtype can be as high as
30%, the construction of consensus sequences has been proposed
as an alternative to cover the required diversity of subtypes
[61,62]. The NL4-3/DRT recombinant vectors described here
might carry optimized sequences of different HIV-1 genes in order
to improve their immunogenicity.
In fact our group has developed a dendritic cell-based vaccine
using autologous inactivated viruses that shows induction of
cellular responses and moderate control of viral load in vaccinated
subjects [34,36]. The generation of autologous inactivated viruses
at levels required for stimulating dendritic cells is a limiting and
time-consuming step. To overcome these hurdles, after proper
modification, the NL4-3/DRT based vectors described here could
be used to generate viral chimeras through the insertion of
genomic fragments amplified directly from plasma RNA or
proviral DNA obtained from HIV infected individuals. This
strategy would allow the production of immature, non-replicative
chimeric viral particles to pulse dendritic cell cultures in order to
induce a strong cellular response against autologous HIV epitopes.
However, our study has a number of drawbacks. First, despite
the detection of significant levels of IFN-c production in the
presence of defective HIV-1 virions in vitro, we did not test the
potential immunological impact of this viral preparation through
other approaches (e.g. the study of T cell polyfunctionality).
Second, the results were generated in vitro in a limited group of
patients and they must be replicated in larger samples. Finally, the
final goal of any therapeutic vaccine is to induce a potent immune
response able to control viral replication in the absence of cART
(‘‘functional cure’’) in a significant proportion of patients, and this
objective needs to be further characterized in clinical trials.
Nonetheless, the present study showed that immature non-
replicative HIV-1 virions generated from NL4-3/DRT represent
effective and safe novel immunogens able to induce strong cellular
responses against HIV in PBMC isolated from many HIV-1
infected individuals, and may therefore represent a promising




NL4-3 plasmid was obtained from the NIH AIDS Research and
Reference Reagent Program (NIH ARRRP, catalogue no. 114)
[63]. pNL4-3/DRT was generated using the previously described
pNL4-3LacZ/RTRen [64]. Briefly, this vector contains the LacZ
gene cloned replacing the RT sequence (2,590 and 3,486 positions
of pNL4-3) and the renilla reporter gene substituting nef (8,797 and
8,887 positions of pNL4-3). To generate the pNL4-3/DRT we
reconstituted the nef gene by cloning 90 bp in NotI/XhoI
restriction sites from pNL4-3. LacZ gene was deleted through
NcoI/AgeI digestion and blunt-end ligation using the Klenow
polymerase. The resulting 13,983 bp plasmid containing HIV-1
plus pUC19 nucleic sequences is termed pNL4-3/DRT (Figure 1)
(patent code EP 11382103.7). The pGag-EGFP vector was
obtained from Dr. G. Pavlakis through the NIH ARRRP
(catalogue no.11468).
Cell Culture
293-T cells were purchased from the American Type Culture
Collection (ATCC, Rockville, MD) (CRL-11268). The TZM-bl
cell line (expressing CD4 receptor and CCR5/CXCR4 co-
receptors, with an integrated LTR-Luc reporter system) [65–68]
was obtained from the NIH ARRRP (catalogue no. 8129). Both
cell lines were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat inactivated fetal bovine
serum (FBS), 2 mM glutamine, penicillin (100 U/ml) and
streptomycin (100 mg/ml) (DMEM-10). All culture media reagents
were from Invitrogen (Madrid, Spain).
PBMCs were isolated from buffy coats of healthy blood donors
(Banc de Sang i Teixits, BST, Barcelona, Spain) by centrifugation
through a ficoll-hypaque gradient. Primary cells were cultured in
RPMI-1640 medium supplemented as described above (RPMI-
10). These cell cultures were supplemented with 100 U/ml human
interleukin (hIL)-2 (SIGMA-ALDRICH, Madrid, Spain) and
5 mg/ml phytohemagglutinin (PHA; SIGMA-ALDRICH) once
every two weeks.
All cell cultures were performed at 37uC in a fully humidified
atmosphere with 5% CO2 in air.
Study Individuals
Samples of EDTA-anticoagulated venous blood samples were
isolated from healthy blood donors and from treated and
untreated chronic asymptomatic HIV-1 individuals with baseline
CD4+ T lymphocyte counts .500 cells/mm3 and plasma viral
loads ranging from 50–10,000 HIV-1 RNA copies/mL (Hospital
Clinic, Barcelona, Spain), by centrifugation through a ficoll-
hypaque gradient and cryopreserved.
All the individuals gave informed written consent and the study
was reviewed and approved by the Institutional Ethical Commit-
tee Board of the Hospital Clinic (Barcelona, Spain).
Generation of Virus Stocks
Viruses were produced by transient transfection in 293-T cells.
Briefly, the previous day 1.56106 293-T cells were seeded in
75 cm2 tissue culture flasks in DMEM-10 medium. Cells were
replaced with fresh DMEM-10 medium three hours before
transfection by the calcium-phosphate method (ProFectionH
Mammalian Transfection System; Promega, Madison, WI)
according to the manufacturer’s instructions, using 5 mg of each
DNA construct previously purified (Qiagen, Valencia, CA).
Growth medium was replaced with fresh DMEM-10 medium
16–18 h post-transfection. For immature wild-type (wt) virion
production, 1 nM APV, corresponding to the IC50 [69], was
added to the medium. The supernatants were harvested approx-
imately two days after transfecton and clarification by centrifuga-
tion at 3500 rpm/4uC for 10 minutes. Virus stocks were
inactivated with AT-2 treatment when required. To this end,
a 100 mM stock solution in DMSO (SIGMA-ALDRICH) was
prepared and added directly to the virus to produce a 1 mM AT-2
solution and treated at 4uC overnight [48,70].
Viral supernatants were concentrated through centrifugation at
28,000 rpm/4uC for 32 minutes (Sorvall Ultra Series WX Ultra
80; Thermo Fisher Scientific, Asheville, NC). The pellets were
centrifuged once more at 40,000 rpm/4uC for 10 minutes and
resuspended in 500 ml 1X PBS before being stored at 280uC.
Viruses were quantified by determining the concentration of p24
in the supernatant with an antigen (Ag) capture assay (ELISA;
Innogenetics NV, Gent, Belgium).
In vitro Infectivity Assay
Viral infectivity (replication) was measured using TZM-bl
marker cells that carry a luciferase gene under the control of the
HIV-LTR. The expression of the luciferase gene in these cells is
repressed by the absence of the Tat protein, and is activated by
HIV-1 replication. Briefly, a 96-well plate was set up with 104
cells/well in the viral stocks previously quantified by p24 antigen
for testing. Viruses were loaded in triplicate with three sets of nine
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serial fourfold dilutions of NL4-3 and NL4-3/DRT viruses as well
as three uninfected controls. The plate was then placed in
a humidified chamber and cultured as described above. The
supernatants were removed after three days of cell culture and the
cell-associated luciferase activity for each well was determined on
a microplate luminometer (Turner Biosystems, Sunnyvale, CA) by
using a luciferase assay kit (BioTherma AB, Dalarb, Sweden).
Confocal Microscopy
293-T cells were transiently transfected as described above with
pGag-EGFP (5 mg) alone, pNL4-3 (3 mg) plus pGag-EGFP (2 mg)
and pNL4-3/DRT (3 mg) plus pGag-EGFP (2 mg). Two days later,
supernatants were collected and used for subsequent infection.
Viruses were quantified by Ag p24. Two mg of p24 of NL4-3/Gag-
EGFP and 2 mg of NL4-3/DRT/Gag-EGFP as well as 1 ml of
Gag-EGFP transfection supernatant were added to 256106
PBMC. After 3–4 hours at 37uC, cells were centrifuged at
1,500 rpm for 5 minutes. Supernantants were discarded and cells
fixed with paraformaldehyde 4% solution (SIGMA-ALDRICH),
stained with DAPI (1/10,000; SIGMA-ALDRICH) and phalloi-
dine (1/1,000; SIGMA-ALDRICH) for 30 minutes at room
temperature, after being mounted in Vectashield mounting
solution (Burlingame, CA). Images were captured using a Leica
SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany)
and processed using ImageJ [http://rsbweb.nih.gov/ij/index.
html].
Electron Microscopy
Virus stocks were produced and concentrated as described
above. Cells were cleaned with 1X PBS, the washing solutions
were removed and the cell monolayers or pelleted viruses were
fixed and kept in 10 ml of glutaraldehyde 2.5% in 1 M PB pH 7.4
at 4uC. After 20 minutes, cells were scraped and transferred to
a 15 ml flask, and pelleted at 1,500 rpm for five minutes. Pellets
were fixed and included in resin according to standard procedures
[71–73]. Electron microscopy images were obtained using a Tecnai
Spirit Twin (FEI, Hillsboro, OR) and processed using ImageJ
[http://rsbweb.nih.gov/ij/index.html]. Morphology quantifica-
tion of 460 NL4-3 and 585 NL4-3/DRT viruses was performed
with 10 different micrographs of 12 mm2 each. Morphology
quantification of 618 NL4-3+ APV particles was performed with
52 different micrographs of 0.6 mm2 each.
Viral Protein Analysis
Purified virions were resuspended in lysis solution. After 15
minutes of incubation at 4uC, samples were centrifuged for 15
minutes at 13,000 rpm at 4uC. Supernatants were collected and
kept at 220uC. Protein concentration was determined by
Bradford reaction (Bio-Rad Laboratories, Madrid, Spain) [74].
For Western blot (WB) 200 ng of the different extracts
quantified by Ag p24 were mixed with Laemmli buffer and
resolved in pre-cast 4–12% Tris-Glycine gels (NovexH 4–12%
Tris-Glycine Mini Gel; Invitrogen). PVDF membranes (Invitro-
gen) were activated for 10 minutes in methanol. Transfer from the
gels to the activated membranes was done in Trans-slot SD semi-
dry transfer cell (Bio-Rad Laboratories) in transfer buffer (NovexH
Tris-Glycine Transfer Buffer (25X); Invitrogen). Membranes were
blocked with 5% skim milk in PBS-0.05% Tween 20 for one hour
and then incubated with an anti-p24 monoclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA). Horseradish peroxidase-
conjugated anti-mouse immunoglobulin G (Santa Cruz Bio-
technology, Santa Cruz, CA) was used as a secondary antibody.
Membranes were treated with a chemiluminescent substrate (Bio-
Rad Laboratories). The bands were visualized and analysed with
a Fujifilm LAS-3000 imager (Fujifilm Life Science USA, Stamford,
CT).
Enzyme-linked Immunospot (ELISPOT) Assay for
Interferon (IFN)-c Release
Ex vivo measurement of T cell-specific IFN-c production was
performed by an ELISPOT assay as previously described [75,76].
Briefly, 96-well plates (Multiscreen Millipore, Bedford, MA) were
coated overnight at 4uC with 15 mg/ml of anti-IFN-c monoclonal
antibody 1-D1K (Mabtech, Stockholm, Sweden) in coating buffer
(Na2CO3 0.1 M, pH 9.6). Plates were washed four times and
blocked with RPMI-1640/10% FBS. Thawed PBMCs were added
to the coated plates for 16–18 h at a final concentration of 105
cells/100 ml. As described above, various virions were also used:
AT-2 inactivated NL4-3; NL4-3/DRT, AT-2 inactivated NL4-3/
DRT and AT-2 inactivated NL4-3 with APV. In all cases we
initially evaluated different doses (range from 200 ng/ml to 5 mg/
ml HIV-1 p24; data not shown). The elicited response was
evaluated against the lowest concentration. Additionally, a negative
control (RPMI-1640/10% FBS) and a positive control (PHA
2 mg/ml; SIGMA-ALDRICH) were performed. Cells were lysed
with PBS/0.05% Tween-20, and wells were incubated for three
hours with 1 mg/ml of biotin-labelled, anti-IFN-c monoclonal
antibody 7-B6-1 (Mabtech). To visualize the spot forming foci
(IFN-c-secreting cells), wells were washed six times and treated for
one hour with streptavidin-alkaline phosphatase (Mabtech). After
this incubation, wells were washed again and 100 ml/well of
chromogenic alkaline-phosphatase conjugated substrate (Bio-Rad
Laboratories) was added. Spots were clearly visible in less than 30
minutes avoiding direct light exposure. Spot forming cells (SFC)
were counted using an AID ELISPOT reader (Autoimmun
Diagnostika GmHb, Strassberg, Germany). Results were ex-
pressed as SFC/106 PBMC after subtracting the background.
The positivity threshold for each construct or antigen was defined
as above 50 SFC/106 PBMC and at least twice that of the control
medium.
Statistical Analysis
Data analysis and comparisons for the different parameters were
made using parametric (paired t test) or non-parametric tests
(Wilcoxon signed rank test), as appropriate. For all analyses, the
level of significance was set at p,0.05. Statistical analysis was
performed using the GraphPad Software, (GraphPad Prism
version 5.00, San Diego California USA).
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